[1]汪玉芳,柯善栋.S100A2在多发性骨髓瘤病人中表达及临床意义[J].青岛大学学报(医学版),2018,54(04):431-434.[doi:10.11712/jms201804013]
 WANG Yufang,KE Shandong.EXPRESSION OF S100A2 IN PATIENTS WITH MULTIPLE MYELOMA AND ITS CLINICAL SIGNIFICANCE[J].JOURNAL OF QINGDAO UNIVERSITY (MEDICAL SCIENCES),2018,54(04):431-434.[doi:10.11712/jms201804013]
点击复制

S100A2在多发性骨髓瘤病人中表达及临床意义()
分享到:

《青岛大学学报(医学版)》[ISSN:2096-5532/CN:37-1217/R]

卷:
第54卷
期数:
2018年04期
页码:
431-434
栏目:
出版日期:
2018-07-05

文章信息/Info

Title:
EXPRESSION OF S100A2 IN PATIENTS WITH MULTIPLE MYELOMA AND ITS CLINICAL SIGNIFICANCE
文章编号:
2096-5532(2018)04-0431-04
作者:
汪玉芳柯善栋
(鄂东医疗集团黄石市中心医院(湖北理工学院附属医院)血液内科,湖北 黄石 435000)
Author(s):
WANG Yufang KE Shandong
(Department of Hematology, Edong Medical Group Huangshi Central Hospital (Hubei Polytechnic University Affiliated Hospital), Huangshi 435000,China)
关键词:
多发性骨髓瘤S100蛋白质类骨髓
Keywords:
multiple myeloma S100 proteins bone marrow
分类号:
R733.3
DOI:
10.11712/jms201804013
文献标志码:
A
摘要:
目的 探讨S100A2在多发性骨髓瘤(MM)病人骨髓单个核细胞中的表达及临床意义。
方法 选取2013年3月—2016年12月在我院初诊的MM病人62例,选取同期因单纯性贫血治疗的35例病人作为对照组。MM病人分别于入院后和4个大疗程结束时,对照组于入院时,采用实时荧光定量PCR技术检测骨髓单个核细胞中S100A2的表达。
结果 MM病人骨髓单个核细胞中S100A2 mRNA相对表达量为1.29±0.12,对照组为2.30±0.17,差异有统计学意义(t=34.127,P<0.01)。MM病人骨髓单个核细胞中S100A2 mRNA相对表达量与国际分期系统(ISS)分期、骨质破坏和髓外浸润有关(t=4.659~50.312,P<0.01)。缓解组MM病人治疗前和治疗后骨髓单个核细胞中S100A2 mRNA相对表达量均高于未缓解组,差异有统计学意义(t=5.289、8.559,P<0.01);两组病人治疗后骨髓单个核细胞中S100A2 mRNA相对表达量均高于治疗前,差异有统计学意义(t′=9.687、5.052,P<0.01)。
结论 S100A2在MM病人骨髓单个核细胞中呈低表达,且其表达与MM发生、进展、浸润及治疗效果有关。
Abstract:
Objective To investigate the expression of S100A2 in the bone marrow mononuclear cells of patients with multiple myeloma (MM) and its clinical significance.
Methods Sixty-two patients newly diagnosed with MM in our hospital from March 2013 to December 2016 were enrolled as subjects. Thirty-five patients with simple anemia within the same period were assigned to control group. The expression of S100A2 in bone marrow mononuclear cells was determined by quantitative real-time PCR among MM patients during admission and after four cycles of major treatment and in the control group during admission.
Results The MM patients had a significantly lower relative S100A2 mRNA level in bone marrow mononuclear cells than the control group (1.29±0.12 vs 2.30±0.17,t=34.127,P<0.01). The relative S100A2 mRNA level in bone marrow mononuclear cells of MM patients was correlated with International Staging System stage, bone destruction, and extramedullary invasion (t=4.659-50.312,P<0.01). The MM patients in the remission group had significantly higher relative S100A2 mRNA levels in bone marrow mononuclear cells before and after treatment than those in the non-remission group, the difference is significant (t=5.289,8.559;P<0.01); in the two groups, the relative S100A2 mRNA levels in bone marrow mononuclear cells were significantly increased after treatment, the difference is significant (t=9.687,5.052;P<0.01).
Conclusion S100A2 has a low expression level in the bone marrow mononuclear cells of patients with MM. The expression of S100A2 is related to the development, progression, invasion, and treatment outcomes of MM.
更新日期/Last Update: 2018-07-08